A comparison of six OCT devices

Article

In a head-to-head comparison of six OCT devices, the Spectralis spectral domain OCT (Heidelberg Engineering) showed the lowest co-efficient of variation in a test-retest study.

In a head-to-head comparison of six OCT devices, the Spectralis spectral domain OCT (Heidelberg Engineering) showed the lowest co-efficient of variation in a test-retest study.

The study, conducted by Dr Ute Wolf-Schnurrbusch and colleagues from the University of Bern, compared central retinal thickness (CRT) measurements in healthy eyes using different commercially available OCT devices and then compared the intersession reproducibility of the measurements. The instruments used were: the Stratus OCT (Carl Zeiss Meditec), SOCT Copernicus (Reichert/Optopol Technology), Spectral OCT/SLO (Opko/OTI), RTVue-100 (Optovue Corporation), Spectralis HRA+OCT and Cirrus HD-OCT (Carl Zeiss Meditec).

The study found that CRT measurements differed significantly between the various devices, with the Spectralis and Cirrus HD-OCT demonstrating higher values than all other instruments. The Spectralis was the only device with a coefficient of variation below 1.0 and the only instrument with a Smallest Measurable Change of less than 2 microns.

“The high repeatability of the Spectralis HRA+OCT measurements is most likely related to the unique feature of the system that allows eye tracking during the scanning process and automatic recognition of the exact same scan location for follow-up examination,” commented Dr Wolf-Schnurrbusch in a Heidelberg press release. “By using this feature for all follow-up scans with the Spectralis HRA+OCT we could minimise extrinsic factors, such as patient fixation and the operator’s ability to consistently place the macular grid over the same points during each scan.”

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.